COVID-19 aggravates limb ischemia in Systemic Scleroderma patients: A case report

Written By :  Aditi
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-01-09 04:00 GMT   |   Update On 2023-01-09 08:13 GMT

Philippines: According to a case report published in BMC Pediatrics, COVID-19 aggravates limb ischemia in Systemic Scleroderma patients. The case report added knowledge on the interaction between COVID-19 and hyperinflammation in the case of rheumatologic disorder.

Juvenile Scleroderma is one of the rare autoimmune diseases of the connective tissue. The concurrence of this autoimmune disorder with COVID-19 can cause limb ischemia because both disease entities are pro-inflammatory and pro-thrombotic. There needs to be more data in this context, and there needs to be more case reports describing the symptomatology and disease course in juvenile Scleroderma and COVID-19 patients.

Advertisement

Addressing and investigating the above concern, a case study was presented by a team of researchers led by Mark Jason D. C. Milan and colleagues from the College of Medicine and Philippine General Hospital.

The case was presented as follows:

  • An adolescent with acute limb ischemia presented and had generalized hypo-and-hyperpigmented skin lesions history.
  • The patient also had a mild, non-productive cough.
  • She tested positive for SARS-CoV-2 on a nasopharyngeal swab detected by RT-PCR.
  • The tests revealed elevated anti-phospholipid antibodies, anti-nuclear antibodies, and D-dimer.
  • Protein S activity was low.
  • There was evidence of peripheral arterial disease in imaging studies.
  • The patient started peripheral vasodilators, Methotrexate, and anticoagulation.
  • The researchers monitored affected limbs and other organs closely.
  • After regular infusion of Cyclophosphamide, limb ischemia was controlled after four months.
  • The multi-disciplinary care was continued for the patient.

To conclude, there is the interplay of COVID-19 hyperinflammatory state, and rheumatologic disorders and this knowledge in this context is evolving.

COVID-19 exacerbates cutaneous manifestations of autoimmune disorders via antigen protein mimicry and cytokine imbalance. COVID-19 and systemic sclerosis exhibit elevated D-dimer, which owe to their pro-thrombotic sequela.

More data must be collected on the association of Protein S activity with COVID-19 and systemic sclerosis. However, more studies are warranted to arrive at a consensus on thrombosis prophylaxis for Scleroderma and COVID-19 patients.

Further reading:

Milan, MJDCMJDC, Dans, LFLF & Torres-Ticzon, V.M.F. Acute limb ischemia in an adolescent with COVID-19 and systemic scleroderma: a case report. B.M.C. Pediatr 22, 737 (2022). https://doi.org/10.1186/s12887-022-03761-w


Tags:    
Article Source : BMC Pediatrics

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News